Company research / Focus view

Lupin

LUPIN · Pharma & Healthcare · mid cap · Midcap 50

Revenue · FY26

₹27,488 cr

+23.9% YoY

What the business sold

Net profit · FY26

₹5,333 cr

+62.5% YoY

What it kept after tax

Operating profit · FY26

₹6,818 cr

+56.9% YoY

Profit from operations

Operating cash flow · FY26

₹7,335 cr

+144.5% YoY

Cash the operations produced

Total debt · FY26

₹6,616 cr

+21.4% YoY

Borrowings against the business

Dividend per share · FY26

—

Paid out per share · not collected yet

Five years in perspective

Price index · Start = 100 · Dividends excluded · ₹2,095 today (+0.83%)

+113.4% · 5Y

2021 · 10020222023202420252026 · 227.0

1M -8.1%6M -10.7%1Y +5.4%3Y +86.0%5Y +113.4%

Market cap

₹95,797 Cr

As of 13 Sept 2026

Price to earnings

17.4

Price to book 4.3

Dividend yield

86.00%

Trailing twelve months

52-week range

₹1,900 – ₹2,530

Closing prices

The financial record

₹ crore · Consolidated where reported · Indian fiscal years (April–March)

Reported metric	FY23	FY24	FY25	FY26
Revenue	16,270	19,656	22,192	27,488
Operating profit	889	2,797	4,345	6,818
Net profit	430	1,914	3,282	5,333
Operating cash flow	1,897	3,648	3,000	7,335
Free cash flow	398	2,719	1,318	5,280
Capital expenditure	-1,500	-929	-1,682	-2,055
Tax expense	269	487	709	1,517
Total debt	4,542	2,922	5,448	6,616
Cash and equivalents	1,232	983	1,544	4,168
Shareholders equity	12,465	14,290	17,204	22,448
Earnings per share (₹)	9.41	41.87	71.69	116.44

Not collected yet for this company: Dividend per share. These come from the filings, not the daily price feed.

Recent quarters

₹ crore · Most recent first

Quarter ended	Revenue	Operating profit	Net profit	EPS (₹)
30 Jun 2026	8,217	2,099	1,415	30.89
31 Mar 2026	7,392	1,724	1,460	31.89
31 Dec 2025	7,100	1,897	1,176	25.67
30 Jun 2025	6,164	1,342	1,219	26.62
31 Mar 2025	5,562	899	773	16.87

Developments

2 positive · 0 negative

NeutralRevenueyesterday

Lupin eyes $500 mn biosimilars revenue in medium term, to ramp capacity

Lupinmid cap

Business Standard13 Sept 2026, 12:27 pm IST

Classification & context · Moves the numbers

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral2 days ago

Tech Query: Lupin, KFin Technologies, KPI Green Energy, Goodluck India - What is the outlook? Where are these stocks headed?

Lupinmid cap GAIL (India)Mentioned

thehindubusinessline.com12 Sept 2026, 8:42 pm IST

Classification & context · Commentary

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Somebody's reading of events rather than an event. Worth the argument; not a filing.

Classifier confidence: 0.35. This is not the probability that the report is true.

NeutralManagement3 days ago

We Can Go Up To Rs 20,000 Cr When It Comes To Acquisitions: Lupin Global CFO - Lupin | Perspective

Lupinmid cap

lupin.com11 Sept 2026, 8:59 pm IST

Classification & context · Commentary

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Somebody's reading of events rather than an event. Worth the argument; not a filing.

Classifier confidence: 0.35. This is not the probability that the report is true.

Reads positiveRegulatory3 days ago

Lupin receives FDA nod for generic Provigil

Lupinmid cap

Drug Store News11 Sept 2026, 6:57 pm IST

Classification & context · Moves the numbers

The headline states a business fact and a direction that helps it. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.80. This is not the probability that the report is true.

Neutral3 days ago

‘Lupin’ Shares Season 4 First-Look Images; ‘Kill Jackie,’ Starring Catherine Zeta-Jones, Releases Trailer (TV News Roundup)

Lupinmid cap

imdb.com11 Sept 2026, 5:11 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral3 days ago

The CHRO has no choice but to become an expert in AI: Lupin’s Yashwant Mahadik

Lupinmid cap

ETHRWorld.com11 Sept 2026, 5:00 am IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral4 days ago

Lupin, Dabur among oversold stocks; analyst explains terminology, strategy

Dabur Indialarge cap LupinMentioned

Business Standard10 Sept 2026, 11:21 am IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral4 days ago

Lupin, Dabur among oversold stocks; analyst explains terminology, strategy

Lupinmid cap Dabur IndiaMentioned

Business Standard10 Sept 2026, 11:21 am IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral4 days ago

Eris, Torrent Pharma, Natco, Lupin stand out in Rs157 billion India GLP-1 opportunity: Kotak

Natco Pharmasmall cap GAIL (India)Mentioned Kotak Mahindra BankMentioned LupinMentioned Torrent PharmaceuticalsMentioned

Moneycontrol.com10 Sept 2026, 11:07 am IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral4 days ago

Eris, Torrent Pharma, Natco, Lupin stand out in Rs157 billion India GLP-1 opportunity: Kotak

Alkem Laboratoriesmid cap GAIL (India)Mentioned Kotak Mahindra BankMentioned LupinMentioned Natco PharmaMentioned Torrent PharmaceuticalsMentioned

Moneycontrol.com10 Sept 2026, 11:07 am IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral5 days ago

Lupin Ltd down for fifth straight session

Lupinmid cap

Business Standard9 Sept 2026, 2:35 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

NeutralRegulatory5 days ago

Lupin gets marketing approval for Pegfilgrastim biosimilar in India

Lupinmid cap GAIL (India)Mentioned

pharma.economictimes.indiatimes.com9 Sept 2026, 10:19 am IST

Classification & context · Moves the numbers

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.35. This is not the probability that the report is true.

NeutralM&A5 days ago

Lupin's US Subsidiary Settles Antitrust Dispute with Humana for $30 Million

Lupinmid cap

scanx.trade9 Sept 2026, 8:58 am IST

Classification & context · Moves the numbers

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.35. This is not the probability that the report is true.

NeutralRegulatory5 days ago

Lupin Receives Tentative Approval from U.S. FDA for Sugammadex Injection

Lupinmid cap

scanx.trade9 Sept 2026, 8:44 am IST

Classification & context · Moves the numbers

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral5 days ago

Lupin Inaugurates Atharv Ability Neuro-Rehabilitation Center in Delhi, Expanding Specialized Care in North India

Lupinmid cap GAIL (India)Mentioned

scanx.trade9 Sept 2026, 8:36 am IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral6 days ago

‘Lupin’ Returns From Prison in New Season 4 First Look Photos

Lupinmid cap

imdb.com8 Sept 2026, 3:03 pm IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Reads positiveRegulatory7 days ago

Lupin Shares Rise on USFDA Nod for Modafinil Tablets

Lupinmid cap

Equitypandit7 Sept 2026, 12:40 pm IST

Classification & context · Moves the numbers

The headline states a business fact and a direction that helps it. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.80. This is not the probability that the report is true.

NeutralRegulatory7 days ago

Lupin receives USFDA approval for Modafinil tablets; share price down marginally

Lupinmid cap

Moneycontrol.com7 Sept 2026, 7:35 am IST

Classification & context · Moves the numbers

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

Names an event that should show up in revenue, profit, debt, capacity or approvals.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral7 days ago

Top stocks in news: JSW Steel, TMCV, Mazagon, RVNL, Lupin, Molbio, Purple Style, HEG, Lemon Tree

JSW Steellarge cap LupinMentioned

Business Today7 Sept 2026, 7:12 am IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

Neutral7 days ago

Stocks To Watch Today: ICICI Bank, RVNL, JSW Steel, Lupin And Brigade Enterprises

JSW Steellarge cap ICICI BankMentioned LupinMentioned

NDTV Profit7 Sept 2026, 7:00 am IST

Classification & context · Routine

No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.

A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.

Classifier confidence: 0.35. This is not the probability that the report is true.

About the business

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies. In addition, it provides chronic therapies, and hospital-based products; products for diabetes and iron supplements for anemia, and a Budesonide-Formoterol combination for asthma. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consisting of labs and collection centers. The company has a strategic collaboration with TB Alliance to support the clinical development and commercialization of Telacebec for the treatment of tuberculosis, leprosy, and buruli ulcer. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Industry: Drug Manufacturers - Specialty & Generic

www.lupin.com

Data confidence

Prices, fundamentals and developments last verified 13 Sept 2026. Fundamentals are sourced from public filings feeds; interpretation is shown separately from figures.

See the Pharma & Healthcare sector →

Sign in to see the full financial record and classified developments

Guests see a sample. Members get every company, five-year fundamentals, classified developments, a watchlist and the decision journal.